ATE196991T1 - Verfahren zur zubereitung von biologisch aktiven komponenten enthaltenden mikrospheren - Google Patents

Verfahren zur zubereitung von biologisch aktiven komponenten enthaltenden mikrospheren

Info

Publication number: ATE196991T1
Authority: AT; Austria
Prior art keywords: biologically active; active components; microspheres containing; containing biologically; preparing microspheres
Prior art date: 1991-05-31

Application number

AT92401433T

Other languages

English (en)

Inventor

Lanfranco Callegaro

Aurelio Romeo

Luca Benedetti

Original Assignee

Fidia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-31

Filing date

1992-05-26

Publication date

2000-11-15

1992-05-26 Application filed by Fidia Spa filed Critical Fidia Spa

2000-11-15 Application granted granted Critical

2000-11-15 Publication of ATE196991T1 publication Critical patent/ATE196991T1/de

Links

239000004005 microsphere Substances 0.000 title abstract 3
150000002148 esters Chemical class 0.000 abstract 3
229920002674 hyaluronan Polymers 0.000 abstract 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 2
229960003160 hyaluronic acid Drugs 0.000 abstract 2
238000013270 controlled release Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Manufacturing Of Micro-Capsules (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT92401433T 1991-05-31 1992-05-26 Verfahren zur zubereitung von biologisch aktiven komponenten enthaltenden mikrospheren ATE196991T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ITPD910102A IT1247472B (it)	1991-05-31	1991-05-31	Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.

Publications (1)

Publication Number	Publication Date
ATE196991T1 true ATE196991T1 (de)	2000-11-15

Family

ID=11389598

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92401433T ATE196991T1 (de)	1991-05-31	1992-05-26	Verfahren zur zubereitung von biologisch aktiven komponenten enthaltenden mikrospheren

Country Status (9)

Country	Link
US (2)	US6066340A (de)
EP (2)	EP0979648A3 (de)
JP (1)	JPH07179363A (de)
AT (1)	ATE196991T1 (de)
CA (1)	CA2070095C (de)
DE (1)	DE69231507T2 (de)
ES (1)	ES2153355T3 (de)
GR (1)	GR3034789T3 (de)
IT (1)	IT1247472B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9221329D0 (en) *	1992-10-10	1992-11-25	Delta Biotechnology Ltd	Preparation of further diagnostic agents
IT1263144B (it) *	1993-02-04	1996-08-01	Lanfranco Callegaro	Composizioni farmaceutiche comprendenti materiale spugnoso costituito da derivati esterei dell'acido ialuronico in associazione con altre sostanze farmacologicamente attive
JPH0827018A (ja) *	1994-07-22	1996-01-30	Sanwa Kagaku Kenkyusho Co Ltd	生理活性ペプチド又は蛋白質を含有する薬剤組成物
EP0817620B1 (de) *	1995-03-28	2002-01-30	Fidia Advanced Biopolymers, S.R.L.	Nanosphären mit einem biokompatiblen polysaccharid
US7276251B2 (en) *	1997-04-01	2007-10-02	Lg Life Sciences, Ltd., Inc.	Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
KR100236771B1 (ko) *	1997-04-01	2000-02-01	성재갑	히아루론산을 이용한 약물의 서방성 미세입자 제형
IT1294797B1 (it)	1997-07-28	1999-04-15	Fidia Advanced Biopolymers Srl	Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante
WO1999059543A1 (en)	1998-05-20	1999-11-25	Highchem Company., Ltd.	A pharmaceutical formulation for nasal administration
JP4610735B2 (ja) *	1998-06-01	2011-01-12	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	ワクチン抗原およびアジュバントの粘膜送達のためのヒアルロン酸ポリマーの使用
US6824793B1 (en)	1998-06-01	2004-11-30	Chiron Corporation	Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
WO2000050078A1 (en)	1999-02-26	2000-08-31	Chiron Corporation	Use of bioadhesives and adjuvants for the mucosal delivery of antigens
AU5624400A (en) *	1999-06-18	2001-01-09	Collaborative Group, Ltd., The	Hyaluronic acid film and matrix for sustained gene transfer
US7582311B1 (en) *	1999-10-15	2009-09-01	Genentech, Inc.	Injection vehicle for polymer-based formulations
GB0004827D0 (en) *	2000-02-29	2000-04-19	Quadrant Holdings Cambridge	Compositions
US6951656B2 (en)	2000-12-22	2005-10-04	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US9700866B2 (en)	2000-12-22	2017-07-11	Baxter International Inc.	Surfactant systems for delivery of organic compounds
US7193084B2 (en)	2000-12-22	2007-03-20	Baxter International Inc.	Polymorphic form of itraconazole
US7037528B2 (en)	2000-12-22	2006-05-02	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US6977085B2 (en)	2000-12-22	2005-12-20	Baxter International Inc.	Method for preparing submicron suspensions with polymorph control
US6884436B2 (en)	2000-12-22	2005-04-26	Baxter International Inc.	Method for preparing submicron particle suspensions
DE10064219B9 (de) *	2000-12-22	2009-02-12	Nasalis Pain Relief International Gmbh	Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US20050048126A1 (en)	2000-12-22	2005-03-03	Barrett Rabinow	Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en)	2000-12-22	2011-11-29	Baxter International Inc.	Method for preparing submicron particles of antineoplastic agents
DE60218375D1 (de) *	2001-03-30	2007-04-12	Chisso Corp	Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen
FR2825273B1 (fr) *	2001-05-29	2006-11-24	Oreal	Composition pour le traitement des signes cutanes du vieillissement
BR0212833A (pt)	2001-09-26	2004-10-13	Baxter Int	Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US20060003012A9 (en)	2001-09-26	2006-01-05	Sean Brynjelsen	Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en)	2001-10-19	2006-09-26	Baxter International Inc.	Compositions of and method for preparing stable particles in a frozen aqueous matrix
US7276254B2 (en) *	2002-05-07	2007-10-02	Xerox Corporation	Emulsion/aggregation polymeric microspheres for biomedical applications and methods of making same
TWI282283B (en) *	2002-05-17	2007-06-11	Wyeth Corp	Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
US20040197264A1 (en) *	2003-04-04	2004-10-07	Alexander Schwarz	Microspheres comprising therapeutic and diagnostic radioactive isotopes
ES2226567B1 (es) *	2003-06-20	2006-07-01	Universidad De Santiago De Compostela	Nanoparticulas de acido hialuronico.
ES2232287B1 (es) *	2003-07-04	2006-11-01	Advanced In Vitro Cell Technologies, S.L.	Nanoparticulas de derivados polioxietilenados.
US8124120B2 (en) *	2003-12-22	2012-02-28	Anika Therapeutics, Inc.	Crosslinked hyaluronic acid compositions for tissue augmentation
ES2246695B1 (es) *	2004-04-29	2007-05-01	Instituto Cientifico Y Tecnologico De Navarra, S.A.	Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
ES2246694B1 (es) *	2004-04-29	2007-05-01	Instituto Cientifico Y Tecnologico De Navarra, S.A.	Nanoparticulas pegiladas.
HUE029021T2 (en)	2005-06-21	2017-02-28	Xoma (Us) Llc	IL-1beta-binding antibodies and fragments thereof
EP3124045A3 (de)	2006-12-20	2017-05-03	Xoma (Us) Llc	Behandlung von il-1-beta-bedingten erkrankungen
WO2008137747A1 (en)	2007-05-02	2008-11-13	The Regents Of The University Of Michigan	Nanoemulsion therapeutic compositions and methods of using the same
US8426467B2 (en)	2007-05-22	2013-04-23	Baxter International Inc.	Colored esmolol concentrate
US8722736B2 (en)	2007-05-22	2014-05-13	Baxter International Inc.	Multi-dose concentrate esmolol with benzyl alcohol
SI2391650T1 (sl)	2007-12-20	2015-03-31	Xoma (Us) Llc	Postopki za zdravljenje protina
ITMI20080981A1 (it) *	2008-05-27	2009-11-28	Fidia Advanced Biopolymers Srl	Processo per la preparazione di microsfere di polimeri semi-sintetici
CN102223876A (zh)	2008-09-26	2011-10-19	纳米生物公司	纳米乳剂治疗性组合物及其使用方法
CA2743904A1 (en)	2008-11-17	2010-05-20	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
CA2765511C (en)	2009-06-16	2015-05-12	The Regents Of The University Of Michigan	Nanoemulsion vaccines
US8658603B2 (en)	2010-06-16	2014-02-25	The Regents Of The University Of Michigan	Compositions and methods for inducing an immune response
GB201017889D0 (en) *	2010-10-22	2010-12-01	Univ Dublin	A polymeric nanoparticle
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
WO2013096516A1 (en)	2011-12-19	2013-06-27	Xoma Technology Ltd.	Methods for treating acne
JP2015509091A (ja)	2012-01-09	2015-03-26	ザスクリプスリサーチインスティテュート	ヒト化抗体
CA2863224A1 (en)	2012-01-09	2013-07-18	The Scripps Research Institute	Ultralong complementarity determining regions and uses thereof
WO2014159759A1 (en)	2013-03-13	2014-10-02	Biosphere Medical, Inc.	Compositions and associated methods for radioisotope-binding microparticles
CA2918370A1 (en)	2013-07-18	2015-01-22	Fabrus, Inc.	Humanized antibodies with ultralong complementarity determining regions
WO2015017146A2 (en)	2013-07-18	2015-02-05	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
JP6822839B2 (ja)	2013-09-13	2021-01-27	ザ・スクリップス・リサーチ・インスティテュート	修飾された治療剤、及びその組成物
CN105814083A (zh)	2013-10-15	2016-07-27	加州生物医学研究所	嵌合抗原受体t细胞开关和其用途
CN105829349B (zh)	2013-10-15	2023-02-03	斯克利普斯研究所	肽嵌合抗原受体t细胞开关和其用途
KR101977449B1 (ko)	2013-11-01	2019-05-10	유니버시티에트 이 오슬로	알부민 변이체 및 이의 용도
DK3069138T3 (en)	2013-11-15	2019-04-08	Univ Oslo Hf	CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
KR102455171B1 (ko)	2013-12-18	2022-10-14	더 스크립스 리서치 인스티튜트	변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
EP4112076A1 (de)	2014-10-10	2023-01-04	The Regents of The University of Michigan	Nanoemulsionszusammensetzungen zur prävention, unterdrückung oder eliminierung von allergischen und entzündlichen erkrankungen
CN107530416A (zh)	2015-03-05	2018-01-02	西北大学	非神经侵染的病毒及其用途
US10800828B2 (en)	2015-03-26	2020-10-13	The Scripps Research Institute	Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en)	2015-04-15	2021-08-17	The Scripps Research Institute	Optimized PNE-based chimeric receptor T cell switches and uses thereof
WO2016205488A1 (en)	2015-06-17	2016-12-22	The California Institute For Biomedical Research	Modified therapeutic agents and compositions thereof
WO2016207730A1 (en)	2015-06-22	2016-12-29	The University Of Oslo	Targeting of vaccine antigen to an intracellular compartment
CN105663052B (zh) *	2016-02-05	2019-03-15	舒泰神（北京）生物制药股份有限公司	神经生长因子缓释微球制剂及其制备方法
US11173207B2 (en)	2016-05-19	2021-11-16	The Regents Of The University Of Michigan	Adjuvant compositions
EP3529268B1 (de)	2016-10-19	2025-02-26	The Scripps Research Institute	Chimäre antigenrezeptor-effektorzellen-switches mit humanisierten targeting-einheiten und/oder optimierten chimären antigen-rezeptor-interaktionsdomänen und verwendungen davon
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
EP3678698A1 (de)	2017-09-07	2020-07-15	University Of Oslo	Impfstoffmoleküle
EP3678699A1 (de)	2017-09-07	2020-07-15	University Of Oslo	Impfstoffmoleküle
EP3807644A4 (de)	2018-06-12	2022-07-06	Angiex, Inc.	Antikörper-oligonukleotid-konjugate
CA3149494A1 (en)	2019-08-12	2021-02-18	Purinomia Biotech, Inc.	Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
CN115551594A (zh)	2019-10-24	2022-12-30	米诺陶治疗公司	经细胞因子修饰的嵌合抗体及其使用方法
KR102296304B1 (ko)	2020-11-30	2021-09-01	조광용	고팽윤성 히알루론산 비드 겔 제조 방법
KR102366394B1 (ko)	2021-01-05	2022-02-23	조광용	고팽윤성 히알루론산 비드 겔
US20240156935A1 (en)	2021-03-31	2024-05-16	Vib Vzw	Vaccine Compositions for Trypanosomatids
US20250197525A1 (en)	2021-04-28	2025-06-19	Minotaur Therapeutics, Inc.	Humanized chimeric bovine antibodies and methods of use
IL316289A (en)	2022-04-29	2024-12-01	Purinomia Biotech Inc	Methods and compositions for treating diseases and disorders driven by eosinophils
WO2025225629A1 (ja) *	2024-04-23	2025-10-30	株式会社メディラボRfp	経鼻投与用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2750090A1 (de) *	1976-11-19	1978-06-01	Sandoz Ag	Neue verabreichungsformen fuer organische verbindungen
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
US4636524A (en)	1984-12-06	1987-01-13	Biomatrix, Inc.	Cross-linked gels of hyaluronic acid and products containing such gels
SE8501022L (sv)	1985-03-01	1986-09-02	Pharmacia Ab	Format alster och forfarande for dess framstellning
US4851521A (en)	1985-07-08	1989-07-25	Fidia, S.P.A.	Esters of hyaluronic acid
WO1987003197A1 (en) *	1985-11-29	1987-06-04	Fisons Plc	Pharmaceutical composition including sodium cromoglycate
GB8601100D0 (en) *	1986-01-17	1986-02-19	Cosmas Damian Ltd	Drug delivery system
US4946870A (en) *	1986-06-06	1990-08-07	Union Carbide Chemicals And Plastics Company Inc.	Delivery systems for pharmaceutical or therapeutic actives
IT1203814B (it)	1986-06-30	1989-02-23	Fidia Farmaceutici	Esteri dell'acido alginico
AU610083B2 (en) *	1986-08-18	1991-05-16	Clinical Technologies Associates, Inc.	Delivery systems for pharmacological agents
JPH0725689B2 (ja) *	1986-10-07	1995-03-22	中外製薬株式会社	顆粒球コロニ−刺激因子を含有する徐放性製剤
US5108759A (en) *	1987-04-01	1992-04-28	Ranney David F	Endothelial envelopment drug carriers
US4883666A (en) *	1987-04-29	1989-11-28	Massachusetts Institute Of Technology	Controlled drug delivery system for treatment of neural disorders
GB8712176D0 (en) *	1987-05-22	1987-06-24	Cosmas Damian Ltd	Drug delivery system
GB8723846D0 (en)	1987-10-10	1987-11-11	Danbiosyst Ltd	Bioadhesive microsphere drug delivery system
JP2670680B2 (ja)	1988-02-24	1997-10-29	株式会社ビーエムジー	生理活性物質含有ポリ乳酸系微小球およびその製造法
IT1219587B (it)	1988-05-13	1990-05-18	Fidia Farmaceutici	Polisaccaridi carbossiilici autoreticolati
US5073543A (en) *	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5008116A (en) *	1988-11-14	1991-04-16	Frederick Cahn	Immunostimulatory microsphere
JP3187410B2 (ja) *	1989-08-10	2001-07-11	住友製薬株式会社	脳内投与用徐放性製剤
US5707644A (en) *	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
GB2237510B (en) *	1989-11-04	1993-09-15	Danbiosyst Uk	Small particle drug compositions for nasal administration
GB9202464D0 (en) *	1992-02-05	1992-03-18	Danbiosyst Uk	Composition for nasal administration
US5879359A (en) *	1992-08-03	1999-03-09	Fidia S.P.A.	Biodegradable guide channels comprised of esters of hyaluronic acid for use in tissue repair as surgical aids
IT1268955B1 (it) *	1994-03-11	1997-03-18	Fidia Advanced Biopolymers Srl	Esteri attivi di polisaccaridi carbossilici
US5874029A (en) *	1996-10-09	1999-02-23	The University Of Kansas	Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) *	1996-10-09	1998-11-10	The University Of Kansas	Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
EP0907721A1 (de) *	1996-05-28	1999-04-14	Brown University Research Foundation	Biologisch abbaubarer träger auf basis von hyaluronan für die gewebewiederherstellung

1991
- 1991-05-31 IT ITPD910102A patent/IT1247472B/it active IP Right Grant
1992
- 1992-05-26 EP EP99202579A patent/EP0979648A3/de not_active Withdrawn
- 1992-05-26 DE DE69231507T patent/DE69231507T2/de not_active Expired - Lifetime
- 1992-05-26 ES ES92401433T patent/ES2153355T3/es not_active Expired - Lifetime
- 1992-05-26 EP EP92401433A patent/EP0517565B1/de not_active Expired - Lifetime
- 1992-05-26 AT AT92401433T patent/ATE196991T1/de not_active IP Right Cessation
- 1992-05-29 JP JP4139012A patent/JPH07179363A/ja active Pending
- 1992-05-29 CA CA002070095A patent/CA2070095C/en not_active Expired - Lifetime
1993
- 1993-12-20 US US08/169,558 patent/US6066340A/en not_active Expired - Lifetime
1999
- 1999-01-13 US US09/231,353 patent/US6039970A/en not_active Expired - Lifetime
2000
- 2000-11-08 GR GR20000402482T patent/GR3034789T3/el unknown

Also Published As

Publication number	Publication date
DE69231507T2 (de)	2001-05-03
EP0979648A2 (de)	2000-02-16
JPH07179363A (ja)	1995-07-18
ITPD910102A0 (it)	1991-05-31
CA2070095A1 (en)	1992-12-01
US6039970A (en)	2000-03-21
CA2070095C (en)	2000-04-25
GR3034789T3 (en)	2001-02-28
EP0979648A3 (de)	2000-10-04
DE69231507D1 (de)	2000-11-23
US6066340A (en)	2000-05-23
EP0517565A2 (de)	1992-12-09
ES2153355T3 (es)	2001-03-01
IT1247472B (it)	1994-12-17
EP0517565B1 (de)	2000-10-18
ITPD910102A1 (it)	1992-12-01
EP0517565A3 (de)	1992-12-30

Legal Events

Date	Code	Title
2001-03-15	UEP	Publication of translation of european patent specification
2004-07-15	EEFA	Change of the company name
2012-02-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE196991T1 (de)	2000-11-15	Verfahren zur zubereitung von biologisch aktiven komponenten enthaltenden mikrospheren
KR960702348A (ko)	1996-04-27	불포화 카르복실산 에스테르 제조용 촉매 및 그의 사용 방법 (Catalyst and Process for Using for the Preparation of Unsaturated Carboxylic Acid Esters)
DE69422064D1 (de)	2000-01-20	Verfahren zur Herstellung von optischaktiven 4-Halo-3-hydroxybuttersäure-Estern
DE69614174D1 (de)	2001-09-06	Verfahren zur Herstellung von optisch-aktiven Gamma-substituierte-Hydroxy-Buttersäure-Ester
DE69015591D1 (de)	1995-02-09	Verfahren zur Herstellung von Estern von ungesättigten Carbonsäuren.
DE68913714D1 (de)	1994-04-14	Verfahren zur Herstellung von ungesättigter Carbonsäure oder ihrem Ester.
PT93874A (pt)	1990-11-20	Processo para a preparacao de esteres de acidos (met)acrilicos contendo um grupo carboxamida e de preparacoes adesivas contendo estes compostos, uteis para o tratamento de materiais contendo colagenio
DE59104023D1 (de)	1995-02-09	Verfahren zur Herstellung von monoethylenisch ungesättigten Carbonsäureestern.
DE69403210D1 (de)	1997-06-19	Verfahren zur herstellung von n-acetylneuraminsäure
DE59205000D1 (de)	1996-02-22	Verfahren zur Herstellung von Hydroxyphenylcarbonsäureestern
DE69007599D1 (de)	1994-04-28	Verfahren zur Racemisierung optisch aktiver Carbonsäureester.
DE69318642D1 (de)	1998-06-25	Verfahren zur Herstellung von Carbonester Verfahren zur Herstellung von Carbonester
DE68913342D1 (de)	1994-04-07	Verfahren zur Herstellung von Carbonsäureestern.
DE68909305D1 (de)	1993-10-28	Verfahren zur Herstellung von Carbonsäureestern.
DE59403829D1 (de)	1997-10-02	Verfahren zur Herstellung von Carbonsäurevinylestern
DE68914233D1 (de)	1994-05-05	Verfahren zur Herstellung von Estern von Tricyclodekancarbonsäuren.
DE69013490D1 (de)	1994-11-24	Verfahren zur Herstellung von Estern von alpha-beta ungesättigten Karbonsäuren.
DE69219363D1 (de)	1997-05-28	VERFAHREN ZUR HERSTELLUNG VON OPTISCH AKTIVEN ALIPHATISCHEN Carbonsäuren
DE59602784D1 (de)	1999-09-23	Verfahren zur Herstellung von Alkylestern der (Meth)acrylsäure
ATE90574T1 (de)	1993-07-15	Deodorierung von guellen mit hilfe von undecylensaeureester.
DE59303045D1 (de)	1996-08-01	Verfahren zur Herstellung von Omega-(O-substituierten Urethano)alkylcarbonsäureestern
ATE86974T1 (de)	1993-04-15	(2-cyan-2-oximinoacetyl)-aminosaeure-derivate.
GR3007585T3 (de)	1993-08-31
DE59006944D1 (de)	1994-10-06	Verfahren zur Herstellung von 2-Mercapto-4-methyl-1,3-thiazol-5-yl-essigsäure und deren Ester.
FR2701944B1 (fr)	1995-05-19	Procédé d'hydroxycarbonylation de lactones en acides dicarboxyliques aliphatiques.